Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1966 3
1970 1
1973 1
1974 1
1975 4
1976 5
1977 1
1979 1
1985 2
1986 1
1988 1
1991 1
1992 1
1995 1
1996 1
1998 1
1999 1
2000 2
2001 1
2002 2
2003 1
2004 2
2005 3
2007 7
2008 9
2009 10
2010 5
2011 4
2012 8
2013 4
2014 5
2015 2
2016 6
2017 11
2018 6
2019 12
2020 17
2021 16
2022 16
2023 11
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
Donanemab in Early Alzheimer's Disease.
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Mintun MA, et al. Among authors: sims jr. N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13. N Engl J Med. 2021. PMID: 33720637 Clinical Trial.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Nanoparticles for Oral Biofilm Treatments.
Benoit DSW, Sims KR Jr, Fraser D. Benoit DSW, et al. Among authors: sims kr jr. ACS Nano. 2019 May 28;13(5):4869-4875. doi: 10.1021/acsnano.9b02816. Epub 2019 Apr 29. ACS Nano. 2019. PMID: 31033283 Free PMC article. Review.
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, Gueorguieva I, Hauck PM, Brooks DA, Mintun MA, Sims JR. Shcherbinin S, et al. Among authors: sims jr. JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793. JAMA Neurol. 2022. PMID: 36094645 Free PMC article. Clinical Trial.
Trial of Solanezumab in Preclinical Alzheimer's Disease.
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS; A4 Study Team. Sperling RA, et al. Among authors: sims jr. N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17. N Engl J Med. 2023. PMID: 37458272 Clinical Trial.
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, Shcherbinin S, Ardayfio P, Sims JR. Lowe SL, et al. Among authors: sims jr. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. doi: 10.1002/trc2.12112. eCollection 2021. Alzheimers Dement (N Y). 2021. PMID: 33614890 Free PMC article.
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA. Pontecorvo MJ, et al. Among authors: sims jr. JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392. JAMA Neurol. 2022. PMID: 36251300 Free PMC article. Clinical Trial.
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.
Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S, VandeVrede L, Chai X, Proctor NK, Airey DC, Shcherbinin S, Duggan Evans C, Sims JR, Zetterberg H, Blennow K, Karydas AM, Teunissen CE, Kramer JH, Grinberg LT, Seeley WW, Rosen H, Boeve BF, Miller BL, Rabinovici GD, Dage JL, Rojas JC, Boxer AL; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators. Thijssen EH, et al. Among authors: sims jr. Nat Med. 2020 Mar;26(3):387-397. doi: 10.1038/s41591-020-0762-2. Epub 2020 Mar 2. Nat Med. 2020. PMID: 32123386 Free PMC article.
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit. Salloway S, et al. Among authors: sims jr. Nat Med. 2021 Jul;27(7):1187-1196. doi: 10.1038/s41591-021-01369-8. Epub 2021 Jun 21. Nat Med. 2021. PMID: 34155411 Free PMC article. Clinical Trial.
167 results